target directory

glucagon like peptide 1 receptor glp 1r clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

target

Association rule

normalized field

NCT02229227

Source recordAI-normalized

Study 200977: Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine in the Treatment of Subjects With Type 2 Diabetes Mellitus: The Switch Study

The Switch Study, sponsored by GlaxoSmithKline, evaluates the efficacy and safety of albiglutide in combination with insulin glargine compared to a traditional basal-bolus insulin regimen in patients with Type 2 Diabetes Mellitus (T2DM) who are not achieving adequate glycemic control. With approximately 794 participants, the study aims to address the growing need for effective diabetes management solutions, particularly in patients struggling with complex insulin regimens. The results may position albiglutide as a viable alternative to conventional insulin therapies, potentially enhancing GSK's portfolio in the diabetes market, which is characterized by intense competition from established players like Novo Nordisk and Sanofi. The findings could influence market dynamics, particularly if albiglutide demonstrates superior efficacy or safety profiles, leading to increased adoption in clinical practice.

AI analysis

Indication: Diabetes Mellitus, Type 2

Modality: small molecule

Target: Glucagon-like peptide-1 receptor (GLP-1R)

Sponsor: GlaxoSmithKline

Source URL: ClinicalTrials.gov

Source updated: Nov 27, 2020

Ingested: Jun 19, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: Glucagon-like peptide-1 receptor (GLP-1R)

View original source fields

Condition raw: Diabetes Mellitus, Type 2

Condition normalized: Diabetes Mellitus, Type 2

Modality raw: small molecule

Modality normalized: small molecule

Target raw: Glucagon-like peptide-1 receptor (GLP-1R)

Target normalized: Glucagon-like peptide-1 receptor (GLP-1R)

Open report

NCT04122716

Source recordAI-normalized

Synergy Effect of the Appetite Hormone GLP-1 (LiragluTide) and Exercise on Maintenance of Weight Loss and Health After a Low Calorie Diet - the S-LiTE Randomized Trial

The S-LiTE trial investigates the synergistic effects of liraglutide, a GLP-1 receptor agonist, combined with exercise on weight loss maintenance and immunometabolic health in obese individuals. Given the rising prevalence of obesity and associated metabolic disorders, this study addresses a significant market need for effective long-term weight management solutions. The trial's outcomes could enhance liraglutide's positioning in the obesity treatment landscape, potentially leading to expanded indications and increased market share. Competitive implications include the need for differentiation from other weight management therapies, particularly those targeting similar patient populations. Diligence considerations should focus on the robustness of the trial design, the potential for positive outcomes, and the implications for future commercialization strategies.

AI analysis

Indication: Obesity